CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
Stocks in this Quantisnow insightHealth Care
Historical context for CDT
Across the 26 sessions after earlier CDT headlines, the stock closed higher 12 times and lower 14 times, with a median move of 9.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CDT | SPY |
|---|---|---|---|
| Sep 2, 2026 | CDT Provides Capital Update and Confirms No Nasdaq Deficiencies | -38.5% | +0.4% |
| Sep 1, 2026 | CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth | -11.9% | -0.7% |
| Aug 28, 2026 | CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio | -10.1% | -0.2% |
| Aug 25, 2026 | CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market | -17.7% | +0.3% |
| Aug 3, 2026 | CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion | -2.2% | +1.4% |
| Jul 20, 2026 | CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane | +13.8% | -0.2% |
Quantisnow market dataNASDAQ
CDT
CDT Equity Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2022
Get push alerts for CDT
Full CDT profile on Quantisnow Follow CDT and get a push notification the moment its next story breaks.